You are here

Our science / Clinical Trials / Find a Trial / NCT00225511

Study Evaluating Effexor XR for Major Depression.

Back to Search Print Save as PDF Bookmark Trial

NCT00225511

Last updated on May 12, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Nagoya, Aichi, 462-0831 Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Depression
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-64 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients diagnosed with major depression based on DSM-IV-TR

- Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the
item of "depressed mood" at the baseline.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with schizophrenia or any other psychotic disorder

- Patients with history or presence of bipolar disorder

NCT00225511
Pfizer
Completed
Study Evaluating Effexor XR for Major Depression.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Depression, Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
NCT00369343
Females
40+
Years
Multiple Sites
Depression
Study Evaluating Effexor XR for Major Depression.
NCT00225511
All Genders
20+
Years
Multiple Sites
Depression
Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.
NCT00225524
All Genders
20+
Years
Multiple Sites
Impotence, Depression
Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction
NCT00159809
Males
Study Evaluating Effexor XR for Major Depression.
Phase III Multi-Center, Double-Blind, Comparative Study of Effexor XR for the Treatment of Depression
Study Evaluating Effexor XR for Major Depression.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Depression
  • Drug: Effexor XR
  • Drug: Milnacipran
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
590
Not Provided
Not Provided

Inclusion Criteria:

  • Patients diagnosed with major depression based on DSM-IV-TR
  • Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of "depressed mood" at the baseline.

Exclusion Criteria:

  • Patients with schizophrenia or any other psychotic disorder
  • Patients with history or presence of bipolar disorder
Sexes Eligible for Study: All
20 Years to 64 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00225511
0600B1-816
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
May 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now